脑膜瘤分子分类器的开发与验证
研究基于1698例脑膜瘤国际队列,构建并严格验证了仅用DNA甲基化数据的机器学习分子分类器。验证队列中各组结局与原始分组几乎一致,高代谢组中位无进展生存期为7.4(4.9-Inf)年,增殖组为2.5(2.3-5.3)年,其他组未达到。该分类器公开可用,可重复原始分子分组的生物学和结局。
要点
- 基于DNA甲基化的机器学习分类器可重复原始4个分子分组的生物学和结局。
- 验证队列高代谢组中位PFS 7.4(4.9-Inf)年,增殖组2.5(2.3-5.3)年,其他组未达到。
- 分类为NF2野生型的肿瘤无NF2突变,51.4%具有该组先前描述的经典突变。
核心结论
- 基于DNA甲基化的分类器可重复原始分子分组的生物学和结局,该分类器公开可用,可供立即临床使用。
研究设计与样本
- 使用1698例脑膜瘤的国际队列,构建并严格验证了仅以DNA甲基化数据为输入的机器学习分子分类器。
- 使用DNA甲基化、RNA测序、拷贝数图谱、全外显子测序和临床结局比较原始与 newly predicted 分子分组。
主要发现
- 验证队列中各组结局与原始描述几乎一致,高代谢肿瘤中位无进展生存期为7.4(4.9-Inf)年,增殖性肿瘤为2.5(2.3-5.3)年,其他组未达到。
- 分类为NF2野生型的肿瘤无NF2突变,51.4%具有该组先前描述的经典突变。
- RNA通路分析显示免疫原性组免疫相关通路上调,高代谢组代谢通路上调,增殖组细胞周期程序上调。
- 批量反卷积显示免疫原性肿瘤中巨噬细胞富集,高代谢和增殖肿瘤中肿瘤细胞富集,比例与原始描述相似。
临床怎么用
- 该DNA甲基化分类器公开可用,可供立即临床使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Meningiomas exhibit considerable clinical and biological heterogeneity. We previously identified 4 distinct molecular groups (immunogenic, NF2-wildtype, hypermetabolic, and proliferative) that address much of this heterogeneity. Despite the utility of these groups, the stochasticity of clustering methods and the use of multi-omics data for discovery limits the potential for classifying prospective cases. We sought to address this with a dedicated classifier. METHODS: Using an international cohort of 1698 meningiomas, we constructed and rigorously validated a machine learning-based molecular classifier using only DNA methylation data as input. Original and newly predicted molecular groups were compared using DNA methylation, RNA sequencing, copy number profiles, whole-exome sequencing, and clinical outcomes. RESULTS: We show that group-specific outcomes in the validation cohort are nearly identical to those originally described, with median progression-free survival (PFS) of 7.4 (4.9-Inf) years in hypermetabolic tumors and 2.5 (2.3-5.3) years in proliferative tumors (not reached in the other groups). Tumors classified as NF2-wildtype had no NF2 mutations, and 51.4% had canonical mutations previously described in this group. RNA pathway analysis revealed upregulation of immune-related pathways in the immunogenic group, metabolic pathways in the hypermetabolic group, and cell cycle programs in the proliferative group. Bulk deconvolution similarly revealed the enrichment of macrophages in immunogenic tumors and neoplastic cells in hypermetabolic and proliferative tumors with similar proportions to those originally described. CONCLUSIONS: Our DNA methylation-based classifier, which is publicly available for immediate clinical use, recapitulates the biology and outcomes of the original molecular groups as assessed using multiple metrics/platforms that were not used in its training.
引用
- Landry AP, Wang JZ, Liu J, et al. Development and validation of a molecular classifier of meningiomas. Neuro Oncol. 2025. PMID: 39775867. doi:10.1093/neuonc/noae242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。